Posted by Michael Wonder on 21 Nov 2022
Bristol Myers Squibb warns US price reforms will dent drug development
20 November 2022 - Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies.
Bristol Myers Squibb says it expects to cancel some drug development programmes due to US government drug pricing rules that are due to be phased in from next year.
